Osteoarthritis accounted for a 26.0% share of the global clinical trials within the Musculoskeletal Disorders therapy area in 2021, registering a decrease of 0.7% when compared with the last ten-year average of 26.7% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Non-industry sponsored trials outnumber industry sponsored trials for Osteoarthritis
Industry sponsored trials held a 35.1% share of all the clinical trials for Osteoarthritis indication in 2021, registering a decrease of 0.5% when compared with the ten-year average of 35.6%. Non-industry sponsored trials accounted for a 64.9% share in 2021, registering an increase of 0.5% over the ten-year average of 64.4%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Osteoarthritis trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Osteoarthritis trials, accounting for a 52.4% share in 2021, when compared with the five-year average of 51.1% and ten-year average of 44.5%.
North America was at the second position with a 31.1% share in 2021, over the five-year average of 27.9% and ten-year average of 30.6%, followed by Europe with a 28.2% share in 2021, as against five-year and ten-year averages of 26.4% and 29.6% respectively.
South and Central America stood fourth with a 3.9% share in 2021, compared with the five-year average of 2.1% and ten-year average of 2.5%, followed by Middle East and Africa with a 2.9% share in 2021, over five-year and ten-year averages of 2.7% and 2.2% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
The US was the top country for industry sponsored Osteoarthritis trials, accounting for a 29.1% share in 2021, as against the five-year average of 25.2% and ten-year average of 27.6%.
China held a 24.3% share in 2021, over the five-year average of 17.7% and ten-year average of 11.4%, followed by India with a 10.7% share in 2021, compared with the five-year and ten-year averages of 11.1% and 10.4% respectively.
Russia held a 9.7% share in 2021, as against the five-year average of 5.4% and ten-year average of 6.8%.
Australia held an 8.7% share in 2021, over the five-year and ten-year averages of 7.0% and 6.2% respectively.
Top regions of non-industry sponsored Osteoarthritis trials
Asia-Pacific was the top region for non-industry sponsored Osteoarthritis trials, accounting for a 53.4% share in 2021 when compared with the five-year average of 55.4% and ten-year average of 47.1%.
North America was at the second position with a 17.4% share in 2021, over the five-year and ten-year averages of 15.9% and 17.1% respectively, followed by Europe with a 15.2% share in 2021, as against the five-year average of 12.8% and ten-year average of 18.3%.
Middle East and Africa stood at the fourth position with a 13.5% share in 2021, compared with the five-year average of 13.8% and ten-year average of 14.6%, followed by South and Central America with a 0.6% share in 2021, over the five-year and ten-year averages of 2.1% and 3.0% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Osteoarthritis trials, accounting for a 29.8% share in 2021, as against the five-year average of 22.6% and ten-year average of 14.9%.
The US held a 16.3% share in 2021, over the five-year average of 13.6% and ten-year average of 14.4%, followed by Iran with a 10.7% share, compared with the five-year and ten-year averages of 11.6% and 11.8% respectively.
India held a 6.7% share in 2021, as against the five-year average of 11.6% and ten-year average of 9.9%.
Thailand held a 5.1% share in 2021, over the five-year average of 3.5% and ten-year average of 3.5%.
Phase II trials lead industry sponsored clinical trials for Osteoarthritis in 2021
Phase II trials held a 34.6% share of industry sponsored clinical trials for Osteoarthritis in 2021, over the five-year average of 40.7% and ten-year average of 40.7%.
Phase I trials held a 32.7% share in 2021, as against the five-year average of 24.0% and ten-year average of 19.1%. Phase III trials held a 25.2% share in 2021, compared with the five-year and ten-year averages of 23.8% and 27.5% respectively.
Phase IV trials held a 7.5% share in 2021, over the five-year average of 11.6% and ten-year average of 12.8%.
Phase II trials lead non-industry sponsored clinical trials for Osteoarthritis in 2021
Phase II trials held a 38.9% share of non-industry sponsored clinical trials for Osteoarthritis in 2021, over the five-year average of 53.1% and ten-year average of 53.2%.
Phase I trials held a 24.7% share in 2021, as against the five-year average of 10.3% and ten-year average of 7.7%. Phase III trials held a 19.2% share, compared with the five-year and ten-year averages of 14.8% and 16.3% respectively.
Phase IV trials held a 17.2% share in 2021, over the five-year average of 21.9% and ten-year average of 22.8%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
